SA Hurvitz

493 citations

45 papers · 315 indexed · h-index 10

Impact in

Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies

Papers in

Oncology 38
- HER2/EGFR in Cancer Research 22
- Cancer Treatment and Pharmacology 21
- Cancer Diagnosis and Treatment 3
Pulmonary and Respiratory Medicine 26
- Advanced Breast Cancer Therapies 21

Co-authors: Fabrice André Mario Campone Ilona Pylvaenaeinen Tarek Sahmoud DJ Slamon H. S. Rugo Steven Applebaum RS Finn
Journals: Cancer Research (23 papers)Journal of Clinical Oncology (9 papers)Annals of Oncology (4 papers)European Journal of Cancer (2 papers)Journal of Thoracic and Cardiovascular Surgery (1 paper)
Partner nations: United States Switzerland Spain

In The Last Decade

SA Hurvitz

43 papers receiving 304 citations

Peers

Countries citing papers authored by SA Hurvitz

Since Specialization

Citations

This map shows the geographic impact of SA Hurvitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SA Hurvitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SA Hurvitz more than expected).

Fields of papers citing papers by SA Hurvitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SA Hurvitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SA Hurvitz. The network helps show where SA Hurvitz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside SA Hurvitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with SA Hurvitz Line = papers co-authored together SA Hurvitz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract P6-18-12: EMBRACA: Efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: A regional analysis Cancer Research ·Leonardo Mina, KH Lee, Anthony Gonçalvès, Natasha Woodward, SA Hurvitz, Sami Diab, Rinat Yerushalmi, Annabel Goodwin, 张祖启, S-B. Kim, Akos Czibere, Sudheer Vemuru, Eric Gauthier, JK Litton, Johannes Ettl	2019	1
2	Abstract P6-18-04: Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis Cancer Research ·Debu Tripathy, Saúl Campos-Gómez, Yen‐Shen Lu, Fábio Franke, Aditya Bardia, Paul Wheatley‐Price, J Handelsman David, 火线, Fátima Cardoso, Enikô Ferenczi, Muskan Shaikh Shaikh, Iván Díaz-Padilla, Michelle C. Miller, SA Hurvitz	2019	1
3	Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial Cancer Research ·Virgil Rouquette-Campredon, Nicholas C. Turner, Audrey Mailliez, Johannes Ettl, M Sulpasso, Sun Li-na, Judith Balmañà, SA Hurvitz, Andrew Wardley, PA Fasching, Corneliu Tudor, Linda Nguyen, S. Z. A. Shah, Mark E. Robson, HS Rugo	2018	3
4	Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial European Journal of Cancer ·Nadia Harbeck, Rafael Villanueva-Vázquez, Debu Tripathy, Yongjin Lu, Michelino De Laurentiis, Sherko Kümmel, D. Taylor, Aditya Bardia, SA Hurvitz, Louis T.C. Chow, S. Im, 柴经国, Gareth Hughes, Michelle C. Miller, Muskan Shaikh Shaikh, David Chandiwana, Marco Colleoni	2018	1
5	116TiP MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR +, HER2– advanced breast cancer (aBC) Annals of Oncology ·Seock‐Ah Im, Louis WC Chow, Zhi‐Ming Shao, Debu Tripathy, Aditya Bardia, SA Hurvitz, Nadia Harbeck, Marco Colleoni, 柴经国, Caroline Germa, Gareth Hughes, Lee Anne McLean, Selma, Amanda Mueller	2015	1
6	Patient-Reported Outcomes (PROS) From EMILIA, a Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine and Lapatinib (XL) In HER2-Positive Locally Advanced or MBC Annals of Oncology ·Manfred Welslau, Véronique Dièras, Joohyuk Sohn, SA Hurvitz, Deepa Lalla, Liang Fang, Ellie Guardino, David Miles	2012	2
7	Exploratory Analysis of the Relationship Between Her2 Expression (BY QRT-PCR) and Efficacy with First-Line Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (HT) in a Randomized Phase 2 Study of Patients (PTS) with HER2-Positive MBC Annals of Oncology ·Edith A. Perez, SA Hurvitz, Lukas C. Amler, Vivian Ng, Ellie Guardino, Luca Gianni	2012	2
8	Abstract P4-08-05: Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo. Cancer Research ·Matthew Kerr, احمد جابر صالحين عبد العزيز, Hayamoto Yamamoto, Yie-Zu Jou, Yunfeng Lu, Volodymyr Korchynskyi, MF Press, SA Hurvitz, DJ Slamon, Wei Lin, Daniela Hübler	2012	1
9	A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC). Journal of Clinical Oncology ·Fabrice André, Thomas Bachelot, Mario Campone, Florence Dalenc, Tom Riel, SA Hurvitz, Nicholas C. Turner, H. S. Rugo, José Baselga, M. Chareton	2011	13
10	Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting. Journal of Clinical Oncology ·A. Guérin, Deepa Lalla, Dominick Latrémouille-Viau, F Moriwaki, Werner H. Schmidt, Melissa Brammer, SA Hurvitz	2011	3
11	Abstract P1-11-12: Phase II Trial of Presurgical Treatment with Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) with Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients with HER2+ Breast Cancer Cancer Research ·Kan Xie, Ravi Patel, David W. Chan, 策之助相澤, Brian DiCarlo, Anne-Véronique Gilles-Raynal, Andrew Kennedy, Fawzi Zghyer, Jeffrey M. Miller, T.G. Khmyzova, А.-А.Э. Алхатов, Ben Convey, DJ Slamon, SA Hurvitz	2010	4
12	Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. Journal of Clinical Oncology ·DJ Slamon, SA Hurvitz, Steven Applebaum, John A. Glaspy, Mariana Viezzer, Keiko OHTA, Rachel Courtney, Doniyor Babajanov, Sophia Randolph, RS Finn	2010	26
13	RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial. Cancer Research ·Ruth O’Regan, Fabrice André, Mario Campone, Philip John Docking, C. Manlius, Ilona Pylvaenaeinen, Tarek Sahmoud, SA Hurvitz	2009	15
14	5001 CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC) European Journal of Cancer Supplements ·Miguel Martín, SA Hurvitz, John F. Kennedy, J. Forbes, H. Roché, Tamás Pintér, W. Eiermann, Marc Buyse, Matthieu Rupin, Audrey V. Sanzogni	2009	1
15	Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer. Cancer Research ·RS Finn, SA Hurvitz, Mary Ann Allison, Steven Applebaum, John A. Glaspy, Keiko OHTA, Ronan Courtney, M. Naveed Shaik, Juan Daniel Arellano Yépez, Camilla Fowst, DJ Slamon	2009	13
16	5021 Everolimus (RAD001) in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab: a multicenter phase I clinical trial European Journal of Cancer Supplements ·SA Hurvitz, 精慈宮川, Mario Campone, C. Manlius, D. Laing, Pabak Mukhopadhyay, Cristian Massacesi, Tarek Sahmoud, Michael Naughton, Fabrice André	2009	2
17	Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab Journal of Clinical Oncology ·Fabrice André, Mario Campone, SA Hurvitz, D. Laing, Ilona Pylvaenaeinen, Tarek Sahmoud, 精慈宮川	2008	43
18	Acute subdural haematoma mimicking an epidural haematoma on a CT scan Brain Injury ·SA Hurvitz, Lance R. Stone, Mary Ann Keenan, Robert L. Waters	1989	4
19	Surgical Treatment of Vertebral Artery Insufficiency in Patients With Diagnosis of Multiple Sclerosis Vascular Surgery ·SA Hurvitz	1977	2
20	Pancreatitis with Biliary Disease Archives of Surgery ·SA Hurvitz	1963	4

About SA Hurvitz

SA Hurvitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Dermatology, having authored 45 papers that have together received 315 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (22 papers), Advanced Breast Cancer Therapies (21 papers), Cancer Treatment and Pharmacology (21 papers), Breast Cancer Treatment Studies (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Fibroblast Growth Factor Research (3 papers), Cancer Diagnosis and Treatment (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). The work is most often cited by research in Oncology (249 citations), Pulmonary and Respiratory Medicine (144 citations), Cancer Research (66 citations), Genetics (35 citations) and Radiology, Nuclear Medicine and Imaging (61 citations). SA Hurvitz has collaborated with scholars based in United States, Switzerland and Spain. Frequent co-authors include Fabrice André, Mario Campone, Ilona Pylvaenaeinen, Tarek Sahmoud, DJ Slamon, H. S. Rugo, Steven Applebaum, RS Finn, John A. Glaspy and José Baselga. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer and Journal of Thoracic and Cardiovascular Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact